Research-informed screening strategy

Pharmacophore-Based Virtual Screening Services: Search by Essential Molecular Features

Pharmacophore screening converts known ligands or protein–ligand interactions into a transparent three-dimensional feature model. It is especially useful for scaffold hopping, focused-library design, and situations where a binding hypothesis is known but a single docking score is not sufficient.

Discuss your project Choose a screening route

Three-dimensional pharmacophore features used to screen diverse compounds

Problems this service solves

Turn Essential Interactions into a Searchable 3D Model

Translate ligand or protein–ligand evidence into a validated feature hypothesis that can search beyond obvious structural analogs.

Different active scaffolds share a hidden interaction pattern

Extract common features and use them to search beyond obvious 2D analogs.

A binding site has defined required contacts

Translate structural interactions into a searchable 3D hypothesis with optional excluded volumes.

Docking produces too many plausible poses

Use a validated feature model as an orthogonal filter or consensus component.

Start from the interaction evidence you already have

Can We Support Your Pharmacophore Screening Project?

Match your ligand or structural evidence to the pharmacophore model we can build, the information required for validation, and the screening outputs you will receive.

Your Starting Point	You Provide	We Build	You Receive
Several credible active ligands but no reliable target structure	SMILES, SDF, or 3D ligand structures Comparable activity values Inactive compounds, if available Assay context and search objective	Ligand curation and conformer generation Alignment and shared-feature analysis Ligand-based pharmacophore hypotheses Active recovery and decoy validation	Selected feature hypothesis Feature definitions and tolerances Validation and sensitivity metrics Model files and interpretation figures
A co-crystal structure or credible protein–ligand complex	PDB file or structure ID Bound ligand and target species Binding-site residues or required contacts Desired library and test capacity	Complex and pocket preparation Interaction-pattern extraction Feature and excluded-volume generation Structure-based model optimization	Structure-derived pharmacophore model Residue-linked feature rationale Excluded volumes and optional features Screening-ready model package
Known required contacts or prohibited regions	Key residues or interaction constraints Reference ligands or mutagenesis evidence Desired and forbidden features Selectivity or off-target requirements	Constraint translation into 3D features Geometry and tolerance optimization Selectivity-oriented excluded volumes Retrospective or expert validation	Testable interaction hypothesis Required and optional feature map Selectivity filters and model limits Candidate-selection criteria
A docking result set that needs orthogonal filtering	Docked poses and compound IDs Target structure and pocket definition Reference interactions or active ligands Property and final-set constraints	Pose-to-feature mapping Pharmacophore fit assessment Consensus filtering with docking evidence Diversity, property, and liability triage	Ranked pharmacophore-consistent hits Feature-mapping visualizations Pose and feature conflict flags Scaffold-diverse experimental shortlist

Minimum starting point: several credible active ligands or one interpretable protein–ligand complex can support an initial model assessment. The validation strategy depends on the quantity, diversity, and comparability of the available evidence.

Illustrative project output

See What a Pharmacophore Screening Project Delivers

A review-ready result connects the biological evidence to a defined feature hypothesis, shows how each candidate maps to that hypothesis, and supplies a traceable shortlist for experimental testing.

Reference Evidence Feature Hypothesis Model Validation Library Matching Test Shortlist

Example two-dimensional ligand residue interaction map beside a three-dimensional pharmacophore feature alignment — Example structural interpretation: a 2D interaction map links the ligand to relevant residues, while the 3D view shows the candidate aligned to aromatic, hydrophobic, donor, or acceptor features. Project figures are labeled with the actual feature definitions and model context.

Explain the match

Why a Candidate Passed the Pharmacophore Filter

A hit is not prioritized from a single fit value. We document the evidence that supports—and limits—the proposed match.

Interaction evidence: the ligands, complex, residues, or experimental observations used to define the model.
Feature hypothesis: required and optional hydrogen-bond, aromatic, hydrophobic, charged, and excluded-volume features.
Spatial agreement: mapped features, alignment geometry, tolerances, and any unmatched requirements.
Candidate context: scaffold diversity, predicted properties, structural alerts, availability, and assay fit.
Decision limits: ambiguous mappings, conformer dependence, and experiments needed to test the hypothesis.

Example Ranked Pharmacophore Matches

The supplied result image has been rebuilt as searchable HTML. It illustrates how compound identity, alignment, and predicted lipophilicity fields can be reviewed together; final columns are configured to the project.

Illustrative data

Priority	Compound ID	Model Sequence	Alignment RMSD	h_logP	logP (o/w)	SlogP
01	HTS11462	27	0.4905	-2.2706	-4.2060	-2.9160
02	HTS01066	16	0.6016	-0.4734	-1.9005	-1.8224
03	BTB09138	11	0.3923	-3.8613	-1.7960	-3.8050
04	JFD01633	28	0.4504	-0.7836	-0.8830	-0.4576
05	HTS06538	25	0.4518	-1.1044	-0.8170	-2.4622
06	HTS00748	15	0.5413	0.7282	-0.7505	-0.8087
07	HTS04935	24	0.3541	-0.3765	-0.6570	-1.8371
08	NRB01133	37	0.2904	0.1677	-0.6170	-0.4807
09	BTB06125	7	0.6686	-0.8133	-0.5760	0.0180
10	HTS02437	20	0.3765	0.2281	-0.4360	0.5459
11	KM06410	34	0.4099	-0.4098	-0.3610	-1.0405
12	HTS03745	23	0.4688	-4.5955	-0.1555	-3.1801
13	HTS02792	21	0.6632	0.2288	-0.0570	0.5383
14	CD09269	13	0.5953	0.3138	0.0221	0.3513
15	BTB06109	6	0.6686	-0.4416	0.0600	0.7313
16	CD09289	14	0.4829	0.6841	0.0861	0.2331
17	HTS07293	26	0.3514	2.1486	0.1280	1.8547
18	HTS03703	22	0.3231	-2.6030	0.1760	-2.3247
19	NH00418	36	0.4959	-3.9312	0.8500	0.7546
20	KM09339	35	0.5535	1.4704	0.9110	1.8781
21	AW00374	1	0.1381	1.5789	1.4460	2.2917
22	KM01565	29	0.5963	1.0043	1.6610	1.4164
23	AW00472	2	0.3224	1.8046	1.8880	2.6818
24	HTS02431	17	0.3417	2.2060	2.0170	2.5700

Alignment evidence

Feature mapping, conformer identity, fit or distance metrics, and visual overlays make the match inspectable.

Property context

Physicochemical fields help identify compounds that meet project-specific property windows before ordering.

Selection rationale

The report separates computational hypotheses from experimental evidence and explains why each compound advances, is reviewed, or is held.

Interpretation note: pharmacophore matches, alignment RMSD, and calculated logP values are model-dependent prioritization evidence—not proof of binding or biological activity. Candidate hypotheses should be confirmed with appropriate biochemical, biophysical, or cellular experiments.

Research applications

Where Pharmacophore Screening Creates Value

The method is selected for the scientific decision—not used as a one-size-fits-all calculation.

Scaffold Hopping

Find chemically distinct molecules that retain the spatial pattern believed to drive activity.

Focused Library Design

Select or assemble a compound set enriched for required interaction features.

Binding-Mode Filtering

Reject docking poses or compounds that fail experimentally supported interaction constraints.

Natural Product Screening

Search structurally diverse collections using features rather than exact substructures.

Selectivity Hypotheses

Encode desired contacts and forbidden regions that distinguish related targets.

Model Interpretation

Create a visual, testable explanation of the features shared by active molecules.

Decision-gated workflow

From Molecular Features to a Validated Hit List

Curate the evidence

Select reliable actives, inactives, complexes, and interaction constraints that can support a feature hypothesis.
Generate hypotheses

Create ligand- or structure-based feature sets with defined geometry, optionality, and excluded volumes.
Validate the model

Measure retrospective enrichment, active recovery, decoy rejection, and sensitivity to conformer generation.
Screen the library

Generate conformers, align compounds to the model, and retain feature mappings for interpretation.
Prioritize diverse matches

Combine fit, feature coverage, novelty, properties, alerts, and availability.
Deliver a testable hypothesis

Provide the model, hits, visual mappings, limits, and an experimental selection strategy.

Quality gates

Three Checks Before a Candidate Is Recommended

Gate 01

Input Fitness

Are the structure, ligand data, target panel, and library suitable for the chosen method?

Gate 02

Evidence Convergence

Do orthogonal scores, interactions, chemistry, and biological context support the same candidates?

Gate 03

Experimental Actionability

Can the shortlist be sourced, tested, interpreted, and used to make the next program decision?

Defined outputs

What Your Pharmacophore Screening Project Delivers

Files, evidence, and recommendations are organized so your team can review the selection logic and move candidates into testing.

Model Package

Feature hypothesis
Tolerances
Excluded volumes

Validation Evidence

Recovery metrics
Enrichment analysis
Sensitivity checks

Screening Results

Ranked matches
Feature maps
Diversity clusters

Decision Report

Shortlist rationale
Model limits
Suggested assays

Related screening methods

Choose the Evidence Route That Matches Your Project

Methods can be used alone or combined as a consensus workflow when the inputs and decision justify it.

FAQs

Frequently Asked Questions

Ligand-based models infer shared features from known actives, while structure-based models derive features from a binding site or protein–ligand complex. Hybrid models can combine both evidence sources.

Yes. A set of credible active ligands can support a ligand-based pharmacophore when their alignment and activity context are sufficiently informative.

Validation can include recovery of known actives, enrichment over decoys, robustness to conformers, and performance on held-out compounds when the dataset allows.

Yes. Pharmacophore matching can filter a library before docking or act as an orthogonal criterion when prioritizing docked poses.